The combination<unk>  product is approved by the United States Food and Drug Administration with an indication for the maintenance treatment of a chronic lung problem called chronic obstructive pulmonary disease (COPD) in adults who (1) have already tried<unk><unk><unk>  (brand name Breo Ellipta) but are still experiencing symptoms of airway obstruction or who want to reduce the risk for COPD exacerbations and (2) are already receiving<unk>  and<unk><unk><unk>  and would like to consolidate their inhaler therapy into a single product. Similarly, in the European Union, FF/UMEC/VI is indicated for the maintenance treatment in adults with moderate to severe COPD who are not adequately treated by an inhaled corticosteroid (ICS) plus long-acting beta-agonist (LABA) combination or a LABA plus long-acting muscarinic antagonist (LAMA) combination. Because FF/UMEC/VI is for maintenance (chronic prophylaxis) treatment, it is not used when people are experiencing acute symptoms consistent with worsening airway obstruction (i.e. COPD exacerbation or an asthma exacerbation). The 2018 National Institute for Health and Care Excellence (NICE) guidelines recommend consideration for ICS/LABA/LAMA triple therapy (like FF/UMEC/VI) provided that the person with COPD has received optimal non-pharmacologic management (e.g. smoking cessation), is experiencing acute COPD exacerbations (either 1 severe exacerbation leading to hospitalization or 2 moderate exacerbations within 1 year), and their COPD has worsened their quality of life. The 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend consideration for triple therapy for people with COPD that—despite ICS/LABA therapy—are persistently breathless, cannot exercise due to their symptoms, or develop further exacerbations. Available forms<unk>  is only available as an inhaler, which generally contains thirty doses (one-month supply) of medicated powder for inhalation (except in the case of, e.g., sample products from the manufacturer or those produced specifically for hospitals institutional formulations, which contain 14 doses). FF/UMEC/VI exists as a dry-powder inhaler, which means that the force of the user's breath causes the medicated powder to leave the device and enter the lungs (unlike, e.g., a metered-dose inhaler which includes a propellant).
Fluticasone furoate/umeclidinium bromide/vilanterol
Beclometasone/formoterol/glycopyrronium bromide
Budesonide/glycopyrronium bromide/formoterol
Budesonide/formoterol
Aclidinium bromide/formoterol
Umeclidinium bromide/vilanterol
Glycopyrronium bromide/formoterol
Olopatadine/mometasone